Loading...
Loading...
PTPI| Name | Value |
|---|---|
| Revenues | 1.4M |
| Cost of Revenue | 1.0M |
| Gross Profit | 0.4M |
| Operating Expense | 2.7M |
| Operating I/L | -2.3M |
| Other Income/Expense | 1.6M |
| Interest Income | 0.1M |
| Pretax | -0.7M |
| Income Tax Expense | 2,072.9M |
| Net Income/Loss | -0.7M |
Petros Pharmaceuticals, Inc. specializes in men's health therapeutics, primarily focusing on the commercialization and development of Stendra, a prescription medication for erectile dysfunction (ED). Additionally, the company is involved in the development and commercialization of H100, a patented topical formulation for the treatment of acute Peyronie's disease. Petros Pharmaceuticals also markets a line of ED products in the form of vacuum erection device products, catering to the needs of individuals seeking solutions for men's health issues.
